LC
WHWK

Lindbrook Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Lindbrook Capital’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-333
Closed -$8K – 2030
2021
Q2 		$8K Buy
+333
New +$7.61K ﹤0.01% 1162
2021
Q1 		– Sell
-145
Closed -$2K – 1956
2020
Q4 		$2K Sell
145
-1,855
-93% -$39.7K ﹤0.01% 1531
2020
Q3 		$45K Buy
+2,000
New +$42.1K 0.01% 383

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Lindbrook Capital's WHWK Position: Q3 2021 in Review

Lindbrook Capital sold out of Whitehawk Therapeutics (WHWK) in Q3 2021, closing a stake of 333 shares — an estimated $8K sold.

Lindbrook Capital first reported a position in WHWK in Q3 2020 and held it in 3 quarters. The position peaked at $45K in Q3 2020. 33 funds tracked by Wall St. Rank hold WHWK as of Q3 2021.

  • Lindbrook Capital reported no remaining Whitehawk Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Lindbrook Capital sold 333 Whitehawk Therapeutics shares in Q3 2021, an estimated $8K.
  • Lindbrook Capital first reported a position in Whitehawk Therapeutics in Q3 2020 and held it in 3 quarters.
  • Lindbrook Capital's Whitehawk Therapeutics position peaked at $45K in Q3 2020.
  • 33 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2021.

Based on Lindbrook Capital's 13F filing for Q3 2021, filed 5 Nov 2021.